Sinopharm (01099.HK) was reduced in shareholding by jpmorgan by 2.6938 million shares.

Gelonghui Finance · Nov 27 06:57

According to the latest equity disclosure data from the Hong Kong Stock Exchange on November 27, 2024, JPMorgan Chase & Co. reduced its shareholding in Sinopharm (01099.HK) at an average price of HK$20.6641 per share on November 21, 2024, by 2.6938 million shares, involving approximately HK$55.6641 million.

After the shareholding reduction, JPMorgan Chase & Co. now holds 118,484,647 shares, with the shareholding ratio decreasing from 9.03% to 8.83%.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

国药控股(01099.HK)遭摩根大通减持269.38万股

Sinopharm (01099.HK) was reduced in shareholding by jpmorgan by 2.6938 million shares.

Risk Disclaimer

Statement